Given the significant effect of DCC-2036 on Bcr-AblT315I CML, we herein evaluated the efficacy of DCC-2036 against the FIP1L1-PDGFRα-expressing cells, including EOL-1 cell line and BaF3 cell lines harboring the WT or T674I FIP1L1-PDGFRα, to examine DCC-2036 as a strategy to overcome the drug-resistance of HES. The gene discussed is FIP1L1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.